Compare SLDP & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLDP | EDIT |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 463.5M | 432.8M |
| IPO Year | 2021 | 2016 |
| Metric | SLDP | EDIT |
|---|---|---|
| Price | $2.27 | $2.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $7.00 | $5.30 |
| AVG Volume (30 Days) | ★ 3.5M | 1.9M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.56 | ★ 37.50 |
| EPS | ★ N/A | N/A |
| Revenue | $21,747,000.00 | ★ $31,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $48.90 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 7.98 | ★ 132.64 |
| 52 Week Low | $1.98 | $1.66 |
| 52 Week High | $8.86 | $4.54 |
| Indicator | SLDP | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 45.78 | 54.20 |
| Support Level | $2.21 | $2.43 |
| Resistance Level | $2.50 | $3.21 |
| Average True Range (ATR) | 0.11 | 0.18 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 44.19 | 61.69 |
Solid Power Inc develops solid-state battery technology and manufacturing processes. Its sulfide-based solid electrolyte material replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells and enables improvement in energy density, battery life and safety performance. The company produces electrolytes on two pilot manufacturing lines using a batch manufacturing process for customer sampling and internal cell development, and manufactures solid-state cells on pre-pilot and pilot cell manufacturing lines. Its cell manufacturing processes are developed around industry-standard lithium-ion battery manufacturing processes and equipment, and it manufactures all cell designs, including cathodes and anodes, using materials sourced from external suppliers.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.